Antimotility agents for the treatment of Clostridium difficile infection: Is the juice worth the squeeze?

Clinical Infectious Diseases

Volumn 48, Issue 5, 2009, Pages 606-608

  Gerding, Dale N ^a,b  

^a HINES VA HOSPITAL   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIARRHEAL AGENT; ANTIMOTILITY AGENT; ATROPINE PLUS DIPHENOXYLATE; COLESTIPOL; COLESTYRAMINE; GASTROINTESTINAL AGENT; LOPERAMIDE; METRONIDAZOLE; UNCLASSIFIED DRUG; VANCOMYCIN;

CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COLON DILATATION; DIARRHEA; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL MOTILITY; HUMAN; NOTE; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; TOXIC MEGACOLON; TREATMENT OUTCOME; COLITIS; DRUG EFFECT; MICROBIOLOGY;

ANTIDIARRHEALS; CLOSTRIDIUM DIFFICILE; COLITIS; HUMANS; TREATMENT OUTCOME;

EID: 60549090317     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/596712     Document Type: Note

References (4)

1. Koo HL, Koo DC, Musher DM, DuPont HL. Antimotility agents for the treatment of Clostridium difficile diarrhea and colitis. Clin Infect Dis 2009; 48:598-605 (in this issue).
2. Wilcox MH, Howe R. Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin. J Antimicrob Chemother 1995; 36:673-9.
3. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353:2433-41.
4. Al-Nassir WN, Sethi AK, Nerandzic MM, Bobulsky GS, Jump RL, Donskey CJ. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis 2008; 47:56-62.